Humoral responses after primary and booster SARS‐CoV‐2 inactivated vaccination in patients with chronic hepatitis B virus infection: A longitudinal observational study. Issue 4 (5th April 2023)

• Record Type: Journal Article
• Authors: Chen, Zhiwei; Huang, Tianquan; He, Taiyu; Zha, Guanhua; Zhu, Qian; Zhang, Gaoli; Xiang, Dejuan; Chen, Min; Li, Hu; Ling, Ning; Lan, Yinghua; Shi, Xiaofeng; Zhang, Dazhi; Xu, Pan; Pan, Qingbo; Song, Rui; Cao, Junxiong; Zhang, Yingzhi; Xiang, Hongyan; Feng, Yali; Yang, Ziqiao; Zhang, Biqiong; Shen, Wei; Cai, Dachuan; Peng, Mingli; Hu, Peng; Ren, Hong
• Is Part Of: Journal of medical virology. Volume 95:Issue 4(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2023-04-05
• Subjects: chronic hepatitis B virus infection -- COVID‐19 -- immunogenicity -- inactivated vaccines -- Omicron variants -- SARS‐CoV‐2; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.28695
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: Given the pandemic of severe acute respiratory syndrome coronavirus 2 Omicron variants, booster vaccination (BV) using inactivated virus vaccines (the third dose) has been implemented in China. However, the immune responses after BV, especially those against Omicron, in patients with chronic hepatitis B virus (HBV) infection (CHB) are unclear. In this prospective longitudinal study, 114 patients with CHB and 68 healthy controls (HCs) were recruited after receiving inactivated vaccination. The anti‐receptor‐binding domain (RBD) immunoglobulin G (IgG), neutralizing antibodies (NAbs), neutralization against Omicron (BA2.12.1, BA.4/5), and specific B/T cells were evaluated. In patients, anti‐RBD IgG was elevated significantly after BV; the titers were as high as those in HCs. Similar results were obtained for the NAbs. However, compared with that against wild type (WT), the neutralization against Omicron was compromised after BV. The frequency of RBD + atypical memory B cells increased, but spike‐specific cluster of differentiation 4 + /8 + T cells remained unchanged after BV. Moreover, no serious adverse events or HBV reactivation were observed after BV. These results suggest that BV significantly enhanced antibody responses against WT; however, it resulted in compromised antibody responses against Omicron in patients with CHB. Hence, new all‐in‐one vaccines and optimal vaccination strategies should be studied promptly.